Skip to main content
Premium Trial:

Request an Annual Quote

Lion Posts Revenue Drop, Ballooning Losses

SAN FRANCISCO, Aug. 7 - Lion Bioscience today reported a decrease in first-quarter revenue on top of expanding net losses.


Total revenue in the quarter ended June 30 decreased to €7.5 million, or roughly $7.3 million, from €8.9 million in the year-ago period, Lion said.


Net loss for the quarter ballooned to €19.2 million, or €.97 per share, from €11.2 million, or €.60 per share, one year ago. The company attributed increased losses to costs integrating NetGenics, acquired in January, as well as a year-over-year drop in revenue.


The company did register an increase in revenue from software licenses, CEO Friedrich von Bohlen said in a statement.


R&D costs increased to €11.6 million for the quarter ended June 30 compared to €10.1 million for the year-ago period.


Lion said it had €37.4 million cash and cash equivalents as of June 30. The company had €66.4 million in short-term marketable securities at the end of the first quarter compared to €104.8 million as of March 31, 2002.


Click here for more information.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.